Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101

MLA

Hans Minderman, et al. “Safety, Efficacy, and Immune Effects of Intratumoral Tilsotolimod in Patients with Refractory Solid Tumours: Updated Results from ILLUMINATE-101.” Annals of Oncology, vol. 30, Oct. 2019, p. v487. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e4c35259ef7b9e5811628f2c3fdeb072&authtype=sso&custid=ns315887.

APA

Hans Minderman, Shah Rahimian, S. Chunduru, Vivek Subbiah, Cara Haymaker, Adi Diab, Hani M. Babiker, Erkut Borazanci, G. Bindra, Orla Maguire, Peter M. Anderson, Chantale Bernatchez, I. Iverson, & Igor Puzanov. (2019). Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101. Annals of Oncology, 30, v487.

Chicago

Hans Minderman, Shah Rahimian, S. Chunduru, Vivek Subbiah, Cara Haymaker, Adi Diab, Hani M. Babiker, et al. 2019. “Safety, Efficacy, and Immune Effects of Intratumoral Tilsotolimod in Patients with Refractory Solid Tumours: Updated Results from ILLUMINATE-101.” Annals of Oncology 30 (October): v487. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........e4c35259ef7b9e5811628f2c3fdeb072&authtype=sso&custid=ns315887.